News
FDA Authorizes Emergency Use of Kineret for Certain Hospitalized COVID-19 Patients
Kineret is an interleukin-1 receptor antagonist.
Your search for supplemental oxygen returned 13 results
ID Week 2022
An Inhaled IFN-ß Treatment May Decrease Risk for Long COVID-19 Symptoms
Patients with COVID-19 who required low-flow oxygen supplementation were randomly assigned to receive either SNG001 (n=314) or placebo (n=309) once daily for 14 days.
ID Week 2022
High-Dose Dexamethasone May Be Harmful for Patients With COVID-19
Current evidence indicates that a 6mg dose of dexamethasone daily is effective for improving COVID-19 outcomes among patients receiving supplemental oxygen.
CHEST 2022
New Machine Learning Tool to Predict Pneumonia Progression Outperforms PSI
Investigators developed and validated a machine learning tool providing an early indication of disease progression in community-acquired pneumonia.
News
Inhaled Nitric Oxide May Ease Severe COVID-19 Pneumonia in Pregnant Women
High-dose inhaled nitric oxide linked to more days free from oxygen supplementation, shorter ICU and hospital length of stay
News
Asian, Black, Hispanic Patients Have Higher Pulse Oximetry Readings
Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity
News
Severe COVID-19 Rates Low With Monoclonal Antibody Therapy During Delta Surge
Rates of severe disease low for high-risk patients with mild-to-moderate COVID-19 treated with antispike monoclonal antibodies
News
Olumiant Approved for COVID-19 Treatment in Hospitalized Adults
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
News
Dapagliflozin Does Not Improve Kidney Outcomes in Hospitalized COVID-19 Cases
Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.
Drugs in the Pipeline
Tocilizumab Gets Priority Review for Treatment of Hospitalized COVID-19 Patients
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
